Imetelstat (Rytelo) for transfusion-dependent LR-MDS post-ESA failure
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-IMETELSTAT |
|---|
| ID | REG-IMETELSTAT-MDS-LR |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-MDS-2021 SRC-IMERGE-PLATZBECKER-2024 SRC-NCCN-AML-2025 |
Notes
Telomerase inhibitor for transfusion-dependent LR-MDS post-ESA failure. Particularly active in non-del(5q) post-ESA setting. Cytopenia dominant toxicity — active management mandatory. STUB — pending Co-Lead sign-off.
Used By
Indication
IND-MDS-LR-2L-IMETELSTAT- IND-MDS-LR-2L-IMETELSTAT